NFKB1 and ovarian cancer: Regarding in vivo studies, TQ has been shown to suppress tumor cell growth in a mouse model of ovarian cancer cells by inhibiting NF-κβ activation [97], while in a syngeneic mouse model of ovarian cancer (ID8-NGL mouse C57BL/6 cells) the efficacy of TQ was limited in the protumorigenic microenvironment, highlighting the need of prolonged TQ treatment (>30 days) as a harmful factor for its efficacy [95].